申请人:Alkermes Pharma Ireland Limited
公开号:US20160137660A1
公开(公告)日:2016-05-19
The present invention provides compounds of formula (I),
wherein:
R
1
is unsubstituted C
1
-C
6
alkyl;
L
a
is substituted or unsubstituted C
1
-C
6
alkyl linker, substituted or unsubstituted C
3
-C
10
carbocycle, substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, or substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S; and
R
2
and R
3
are each, independently, H, substituted or unsubstituted C
1
-C
6
alkyl, or substituted or unsubstituted C
6
-C
10
aryl;
or alternatively, R
2
and R
3
, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S or a substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S.
The invention also provides pharmaceutical compositions and methods for treating neurological diseases, such as multiple sclerosis.
本发明提供式(I)的化合物,其中:R1是未取代的C1-C6烷基;La是取代或未取代的C1-C6烷基连接物,取代或未取代的C3-C10碳环,包含一个或两个5-或6-成员环和1-4个从N,O和S中选择的杂原子的取代或未取代的杂环,或者是取代或未取代的含有一个或两个5-或6-成员环和1-4个从N,O和S中选择的杂原子的取代或未取代的杂芳基;R2和R3各自独立地是H,取代或未取代的C1-C6烷基,或取代或未取代的C6-C10芳基;或者,R2和R3与它们附着的氮原子一起形成取代或未取代的杂芳基,其中包括一个或两个5-或6-成员环和1-4个从N,O和S中选择的杂原子,或取代或未取代的含有一个或两个5-或6-成员环和1-4个从N,O和S中选择的杂原子的杂环。本发明还提供用于治疗神经系统疾病,如多发性硬化症的药物组合物和方法。